Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

VRC07-523LS · VRC07

Monoclonal antibody · Antagonist of HIV-1 envelope glycoprotein gp120

Phase 1 Most advanced trial
1 Registered trials

What is VRC07-523LS?

VRC07-523LS is a monoclonal antibody administered by intravenous infusion. It is being studied in HIV infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
VRC07
Drug type
Monoclonal antibody
Targets
HIV-1 envelope glycoprotein gp120
Mechanism
Antagonist of HIV-1 envelope glycoprotein gp120
Therapy area
Infectious disease
In trials of
IBRX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
EXL0L74IKU

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04340596 Phase 1 HIV Infection Active not recruiting IBRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HIV Infection

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.